[{"address1": "18702 N. Creek Parkway", "address2": "Suite 100", "city": "Bothell", "state": "WA", "zip": "98011", "country": "United States", "phone": "610-321-3700", "website": "https://immunome.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.", "fullTimeEmployees": 55, "companyOfficers": [{"maxAge": 1, "name": "Dr. Clay B. Siegall Ph.D.", "age": 62, "title": "President, CEO & Chairman", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 1433088, "exercisedValue": 0, "unexercisedValue": 12996163}], "auditRisk": 10, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 14.97, "open": 15.26, "dayLow": 15.1, "dayHigh": 16.0548, "regularMarketPreviousClose": 14.97, "regularMarketOpen": 15.26, "regularMarketDayLow": 15.1, "regularMarketDayHigh": 16.0548, "beta": 1.664, "forwardPE": -7.0, "volume": 728733, "regularMarketVolume": 728733, "averageVolume": 835295, "averageVolume10days": 1051850, "averageDailyVolume10Day": 1051850, "bid": 15.71, "ask": 15.77, "bidSize": 200, "askSize": 100, "marketCap": 944108544, "fiftyTwoWeekLow": 4.5, "fiftyTwoWeekHigh": 30.958, "priceToSalesTrailing12Months": 67.34973, "fiftyDayAverage": 21.2432, "twoHundredDayAverage": 12.7919, "currency": "USD", "enterpriseValue": 799683328, "floatShares": 44099719, "sharesOutstanding": 59943400, "sharesShort": 3747870, "sharesShortPriorMonth": 3008878, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.062800005, "heldPercentInsiders": 0.18024999, "heldPercentInstitutions": 0.39891, "shortRatio": 6.26, "shortPercentOfFloat": 0.0664, "bookValue": 2.772, "priceToBook": 5.681818, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -106806000, "trailingEps": -5.38, "forwardEps": -2.25, "enterpriseToRevenue": 57.047, "enterpriseToEbitda": -28.286, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "IMNM", "underlyingSymbol": "IMNM", "shortName": "Immunome, Inc.", "longName": "Immunome, Inc.", "firstTradeDateEpochUtc": 1601645400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c2147e86-3bc9-3a00-bf6a-53fc4499717d", "gmtOffSetMilliseconds": -14400000, "currentPrice": 15.75, "targetHighPrice": 38.0, "targetLowPrice": 33.0, "targetMeanPrice": 35.33, "targetMedianPrice": 35.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 142151008, "totalCashPerShare": 2.381, "ebitda": -28271000, "totalDebt": 1650000, "quickRatio": 6.525, "currentRatio": 6.629, "totalRevenue": 14018000, "debtToEquity": 1.376, "revenuePerShare": 0.706, "returnOnAssets": -0.20807, "returnOnEquity": -1.56452, "freeCashflow": 2356000, "operatingCashflow": -7568000, "grossMargins": -0.6354, "ebitdaMargins": -2.0167599, "operatingMargins": -3.6202302, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]